
CISENDO®Endometrial Cancer Methylation Test (CDO1/CELF4)
World's first non-invasive endometrial cancer screening, filling a clinical gap
CDO1/CELF4 dual-gene methylation test using non-invasive sampling to replace invasive biopsy — the world's first non-invasive endometrial cancer screening, filling a clinical gap.
Recommended companion kits
Use the DNA Isolation and Purifying Kit (Beijing Medical Device No. 20210020) for DNA extraction and purification, followed by DNA Methylation-Lightning MagPrep (Beijing Medical Device No. 20200110) for bisulfite conversion.
Robust clinical data support
Based on multi-center registered clinical trials, sensitivity and specificity both reach industry-leading levels.
Who needs this test?
- Women with abnormal uterine bleeding
- Endometrial cancer screening for postmenopausal women
- Endometrial pathology risk assessment for perimenopausal women
- High-risk women scheduled for hysteroscopy
How is it applied clinically?
- Non-invasive early screening for endometrial cancer
- Pre-hysteroscopy risk stratification to reduce unnecessary invasive procedures
- Follow-up and monitoring for high-risk populations
- Women's health screening programs at health checkup centers
Why choose us
World's first non-invasive endometrial cancer methylation test
Global patents, CE certification, and Malaysia registration
Recommended by the Chinese Expert Consensus on Three-Tier Prevention Strategies for Endometrial Cancer
Recommended by the Expert Consensus on Clinical Application of Gene Methylation Screening for Endometrial Cancer
Frequently asked questions about this test
What is the CISENDO test?
CISENDO is a Class III in vitro diagnostic device (NMPA Reg. No. 20243402610) that detects CDO1/CELF4 dual-gene methylation in cervical exfoliated cells — the world's first non-invasive endometrial cancer screening test.
How accurate is the CISENDO test?
Registration clinical trial data (4,818 samples) show 94.51% sensitivity for endometrial cancer and 94.16% specificity, supported by a 12,000-sample real-world multi-center study.
Can CISENDO replace hysteroscopy or endometrial biopsy?
CISENDO is a non-invasive screening tool using cervical exfoliated cells to assess endometrial cancer risk and reduce unnecessary invasive procedures. Definitive diagnosis still requires hysteroscopy/biopsy pathology, but CISENDO serves as an efficient first-line risk stratifier.
Why test methylation for abnormal uterine bleeding?
Abnormal uterine bleeding is the most common presenting symptom of endometrial cancer. Methylation testing non-invasively assesses malignancy risk, helping clinicians decide whether further invasive examination is needed — avoiding both delay and over-investigation.
Who is suitable for the CISENDO test?
Women with abnormal uterine bleeding, postmenopausal women, perimenopausal women at risk of endometrial lesions, and high-risk women scheduled for hysteroscopy.
Request the IFU, clinical summary and pricing
Tell us your institution type and intended use. We reply within 1–2 business days with the documents below, and can arrange a technical call with our clinical team.
- IFU, registration certificate and sample requirements
- Clinical performance summary and published papers
- Distributor terms, kit configuration and logistics
The same methylation platform, two more cancers
CISPOLY covers cervical, endometrial and ovarian cancer with one non-invasive workflow.
Endometrial Cancer Related Publications

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimens
Journal: Frontiers in Medicine
Affiliation: Gansu Provincial Maternity and Child-care Hospital
DOI: 10.3389/fmed.2026.1690020

Diagnostic Accuracy and Concordance of Self-Collected Cervical CDO1 and CELF4 Methylation Testing Compared With Physician Sampling for Endometrial Cancer
Journal: JCO Precision Oncology
Affiliation: The Second Xiangya Hospital of Central South University
DOI: 10.1200/PO-25-01081

CDO1 and CELF4 methylation assay as the dominant predictor of endometrial cancer: A cohort analysis across pre- and post-menopausal cohorts
Journal: Gynecologic Oncology
Affiliation: Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University)
DOI: 10.1016/j.ygyno.2026.01.776

The endometrial cancer detection using non-invasive hypermethylation of CDO1 and CELF4 genes in women with postmenopausal bleeding in Northwest China
Journal: CytoJournal
Affiliation: Gansu Provincial Maternity and Child-care Hospital
DOI: 10.25259/Cytojournal_78_2023

DNA methylation detection is a significant biomarker for screening endometrial cancer in premenopausal women with abnormal uterine bleeding
Journal: International Journal of Gynecological Cancer
Affiliation: The Third Xiangya Hospital, Central South University
DOI: 10.1136/ijgc-2024-005723

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimens
Journal: Frontiers in Medicine
Affiliation: Gansu Provincial Maternity and Child-care Hospital
DOI: 10.3389/fmed.2026.1690020

Diagnostic Accuracy and Concordance of Self-Collected Cervical CDO1 and CELF4 Methylation Testing Compared With Physician Sampling for Endometrial Cancer
Journal: JCO Precision Oncology
Affiliation: The Second Xiangya Hospital of Central South University
DOI: 10.1200/PO-25-01081

CDO1 and CELF4 methylation assay as the dominant predictor of endometrial cancer: A cohort analysis across pre- and post-menopausal cohorts
Journal: Gynecologic Oncology
Affiliation: Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University)
DOI: 10.1016/j.ygyno.2026.01.776

The endometrial cancer detection using non-invasive hypermethylation of CDO1 and CELF4 genes in women with postmenopausal bleeding in Northwest China
Journal: CytoJournal
Affiliation: Gansu Provincial Maternity and Child-care Hospital
DOI: 10.25259/Cytojournal_78_2023

DNA methylation detection is a significant biomarker for screening endometrial cancer in premenopausal women with abnormal uterine bleeding
Journal: International Journal of Gynecological Cancer
Affiliation: The Third Xiangya Hospital, Central South University
DOI: 10.1136/ijgc-2024-005723










